
    
      This is a Phase 2a, randomized, double-blind, placebo-controlled, parallel-group, multicenter
      study in adult subjects with moderately to severely active Crohn's disease.

      Eligible subjects include males and females aged 18-75 years with moderately to severely
      active CD for at least 3 months. Each subject will receive the assigned treatment over 12
      weeks, followed by a 4-week safety follow-up period.
    
  